PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33771701-0 2021 Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance. Cisplatin 26-35 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 35490795-0 2022 Induction of ferroptosis by carnosic acid-mediated inactivation of Nrf2/HO-1 potentiates cisplatin responsiveness in OSCC cells. Cisplatin 89-98 NFE2 like bZIP transcription factor 2 Homo sapiens 67-71 34237431-5 2021 Moreover, the Nrf2/Keap1 pathway also regulated the sensitivity to cisplatin and PRLX93936 in NSCLC cells. Cisplatin 67-76 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 35464301-0 2022 All-trans-retinoic acid induces RARB-dependent apoptosis via ROS induction and enhances cisplatin sensitivity by NRF2 downregulation in cholangiocarcinoma cells. Cisplatin 88-97 NFE2 like bZIP transcription factor 2 Homo sapiens 113-117 35464301-14 2022 ATRA also suppressed cisplatin-induced NRF2 expression, suggesting that the enhancement of cisplatin cytotoxicity by ATRA may be associated with the downregulation of NRF2 signaling. Cisplatin 21-30 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 35464301-14 2022 ATRA also suppressed cisplatin-induced NRF2 expression, suggesting that the enhancement of cisplatin cytotoxicity by ATRA may be associated with the downregulation of NRF2 signaling. Cisplatin 21-30 NFE2 like bZIP transcription factor 2 Homo sapiens 167-171 35464301-14 2022 ATRA also suppressed cisplatin-induced NRF2 expression, suggesting that the enhancement of cisplatin cytotoxicity by ATRA may be associated with the downregulation of NRF2 signaling. Cisplatin 91-100 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 35464301-14 2022 ATRA also suppressed cisplatin-induced NRF2 expression, suggesting that the enhancement of cisplatin cytotoxicity by ATRA may be associated with the downregulation of NRF2 signaling. Cisplatin 91-100 NFE2 like bZIP transcription factor 2 Homo sapiens 167-171 34856444-0 2022 Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3beta/Fyn pathway. Cisplatin 54-63 NFE2 like bZIP transcription factor 2 Homo sapiens 114-118 34673143-10 2021 NRF2 knockdown and GSH depletion also augmented cisplatin cytotoxicity in A549 cells, whereas auranofin had no effect. Cisplatin 48-57 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 34407971-12 2021 NRF2 also mediated cisplatin sensitivity in endogenously overexpressing primary HPV-related HNSCC cells. Cisplatin 19-28 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 34320371-5 2021 Based on the findings of thirteen tumor entities, we identified three resistance groups, where group 1 (endodermal origin) prominently indicates NRF2-pathway activation, group 2 (mesodermal origin, primordial germ cells) shares elevated DNA repair mechanisms and decreased apoptosis induction, and group 3 (ectodermal and paraxial mesodermal origin) commonly presents deregulated apoptosis induction and alternating pathways as the main cisplatin-induced resistance mechanisms. Cisplatin 437-446 NFE2 like bZIP transcription factor 2 Homo sapiens 145-149 34786050-13 2021 CONCLUSION: These results provide a theoretical basis for further targeting the transcription factors, including Nestin1 and Nrf2, in the treatment of BC with cisplatin. Cisplatin 159-168 NFE2 like bZIP transcription factor 2 Homo sapiens 125-129 34264023-5 2022 METHODS AND RESULTS: We immunolocalized Nrf2 signaling proteins in 69 patients with lymph node metastases, who received NACRT with 5-fluorouracil and cisplatin before esophagectomy. Cisplatin 150-159 NFE2 like bZIP transcription factor 2 Homo sapiens 40-44 34080212-0 2021 Combination of cyanidin-3-O-glucoside and cisplatin induces oxidative stress and apoptosis in HeLa cells by reducing activity of endogenous antioxidants, increasing bax/bcl-2 mRNA expression ratio, and downregulating Nrf2 expression. Cisplatin 42-51 NFE2 like bZIP transcription factor 2 Homo sapiens 217-221 34239803-0 2021 Activation of MEK1/2/Nrf-2 Signaling Pathway by Epstein-Barr Virus-Latent Membrane Protein 1 Enhances Autophagy and Cisplatin Resistance in T-Cell Lymphoma. Cisplatin 116-125 NFE2 like bZIP transcription factor 2 Homo sapiens 21-26 34239803-9 2021 In conclusion, EBV-LMP1 promotes cell autophagy after DDP treatment by activating the MEK1/2/Nrf-2 signaling pathway in lymphoma cells, thus, enhancing the resistance of lymphoma cells to DDP. Cisplatin 54-57 NFE2 like bZIP transcription factor 2 Homo sapiens 93-98 34098867-0 2021 Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cisplatin 54-63 NFE2 like bZIP transcription factor 2 Homo sapiens 108-112 34098867-15 2021 Additionally, cisplatin-resistant cells exhibited stronger activation of Nrf2/Keap1/xCT signaling relative to parental cells, which was restrained by ATF3 up-regulation. Cisplatin 14-23 NFE2 like bZIP transcription factor 2 Homo sapiens 73-77 34098867-16 2021 Importantly, restoring Nrf2 signaling overturned ATF3-mediated ferroptosis and cisplatin resistance. Cisplatin 79-88 NFE2 like bZIP transcription factor 2 Homo sapiens 23-27 35626727-7 2022 iTRAQ proteomics showed that SIRT1/Nrf2 signaling and MT1 proteins were downregulated in cisplatin-treated mouse testes. Cisplatin 89-98 NFE2 like bZIP transcription factor 2 Homo sapiens 35-39 35580917-0 2022 Vinpocetine enhances cisplatin sensitivity of non-small cell lung cancer cells by reducing the nuclear factor erythroid 2-related factor 2 signaling. Cisplatin 21-30 NFE2 like bZIP transcription factor 2 Homo sapiens 95-138 35580917-9 2022 In addition, treatment with vinpocetine suppressed protein expression of Nrf2 and inhibited messenger RNA levels of heme oxygenase 1 and NAD(P)H dehydrogenase quinone 1 induced by cisplatin. Cisplatin 180-189 NFE2 like bZIP transcription factor 2 Homo sapiens 73-77 35490795-9 2022 Furthermore, compared with parental cells, stronger activation of the Nrf2/HO-1/xCT signaling was observed in cisplatin-resistant cells, which was inhibited by carnosic acid. Cisplatin 110-119 NFE2 like bZIP transcription factor 2 Homo sapiens 70-74 35490795-10 2022 Of interest, reactivating the Nrf2 signaling reversed carnosic acid-evoked ferroptosis in cisplatin-resistant cells and ultimately attenuated carnosic acid-mediated cell sensitivity to cisplatin. Cisplatin 90-99 NFE2 like bZIP transcription factor 2 Homo sapiens 30-34 35490795-10 2022 Of interest, reactivating the Nrf2 signaling reversed carnosic acid-evoked ferroptosis in cisplatin-resistant cells and ultimately attenuated carnosic acid-mediated cell sensitivity to cisplatin. Cisplatin 185-194 NFE2 like bZIP transcription factor 2 Homo sapiens 30-34 35490795-11 2022 Together, the current findings highlight that carnosic acid may re-sensitize cisplatin-resistant cells to cisplatin by inducing ferroptosis, which involves the inactivation of Nrf2/HO-1/xCT pathway. Cisplatin 77-86 NFE2 like bZIP transcription factor 2 Homo sapiens 176-180 35490795-11 2022 Together, the current findings highlight that carnosic acid may re-sensitize cisplatin-resistant cells to cisplatin by inducing ferroptosis, which involves the inactivation of Nrf2/HO-1/xCT pathway. Cisplatin 106-115 NFE2 like bZIP transcription factor 2 Homo sapiens 176-180 35505963-7 2022 Furthermore, we demonstrated that miR-6077 protects LUAD cells from cell death induced by CDDP/PEM via CDKN1A-CDK1-mediated cell-cycle arrest and KEAP1-NRF2-SLC7A11/NQO1-mediated ferroptosis, thus resulting in chemoresistance in multiple LUAD cells both in vitro and in vivo. Cisplatin 90-94 NFE2 like bZIP transcription factor 2 Homo sapiens 152-156 35468014-0 2022 Luteolin attenuated cisplatin-induced cardiac dysfunction and oxidative stress via modulation of Keap1/Nrf2 signaling pathway. Cisplatin 20-29 NFE2 like bZIP transcription factor 2 Homo sapiens 103-107 35468014-7 2022 In HL-1 cells, Lut was observed to dramatically reduce cisplatin-induced apoptosis and oxidative stress by modulating the Kelch-like epichlorohydrin-associated protein 1 (Keap1)/Nrf2 pathway. Cisplatin 55-64 NFE2 like bZIP transcription factor 2 Homo sapiens 178-182 35327653-4 2022 Here, we found that NRF2 activation by sulforaphane (SFN) reduced cisplatin (CDDP)-induced cell death only in NRF2-proficient cells (NRF2-ctr) compared to NRF2-Cas9 cells. Cisplatin 66-75 NFE2 like bZIP transcription factor 2 Homo sapiens 110-114 35327653-4 2022 Here, we found that NRF2 activation by sulforaphane (SFN) reduced cisplatin (CDDP)-induced cell death only in NRF2-proficient cells (NRF2-ctr) compared to NRF2-Cas9 cells. Cisplatin 66-75 NFE2 like bZIP transcription factor 2 Homo sapiens 133-137 35327653-4 2022 Here, we found that NRF2 activation by sulforaphane (SFN) reduced cisplatin (CDDP)-induced cell death only in NRF2-proficient cells (NRF2-ctr) compared to NRF2-Cas9 cells. Cisplatin 77-81 NFE2 like bZIP transcription factor 2 Homo sapiens 20-24 35327653-4 2022 Here, we found that NRF2 activation by sulforaphane (SFN) reduced cisplatin (CDDP)-induced cell death only in NRF2-proficient cells (NRF2-ctr) compared to NRF2-Cas9 cells. Cisplatin 77-81 NFE2 like bZIP transcription factor 2 Homo sapiens 110-114 35327653-6 2022 Finally, we found that ZnCl2 supplementation rescued the cisplatin cytotoxic effects, as it impaired NRF2 activation, restoring p53 activity. Cisplatin 57-66 NFE2 like bZIP transcription factor 2 Homo sapiens 101-105 33610575-0 2021 Vincamine protects against cisplatin induced nephrotoxicity via activation of Nrf2/HO-1 and hindering TLR4/ IFN-gamma/CD44 cells inflammatory cascade. Cisplatin 27-36 NFE2 like bZIP transcription factor 2 Homo sapiens 78-82 33735393-0 2021 Sensitization of A-549 lung cancer cells to Cisplatin by Quinacrine-loaded lipidic nanoparticles via suppressing Nrf2 mediated defense mechanism. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 113-117 33735393-2 2021 By harnessing liposome as an advanced nanoparticles transporter, we formulated Quinacrine known as nrf2 inhibitor into nano-carrier, and sensitized A-549 lung tumor cells to Cisplatin. Cisplatin 174-183 NFE2 like bZIP transcription factor 2 Homo sapiens 99-103 33148531-7 2021 Nrf2 knockdown experiment in NSCLC cells obliterated the effect of Trigonelline- Cisplatin and Trigonelline-Etoposide combination, indicating the role of Nrf2 inhibition in augmenting drug sensitivity. Cisplatin 81-90 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 33290263-0 2020 Enhancer-bound Nrf2 licenses HIF-1alpha transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells. Cisplatin 79-88 NFE2 like bZIP transcription factor 2 Homo sapiens 15-19 33219317-10 2021 Experiments using genetic depletion and pharmacological activation in vitro and in vivo demonstrated that UFBP1 enhances the sensitivity of gastric cancer cells to cisplatin through the Nrf2/AKR1C axis. Cisplatin 164-173 NFE2 like bZIP transcription factor 2 Homo sapiens 186-190 33290263-3 2020 We find that Nrf2 is responsible for cisplatin resistance under hypoxia, as Nrf2 knockdown sensitizes HepG2/DDP cells while Nrf2 hyper-activation (though KEAP1 knockdown) increases resistance of HepG2 cells to cisplatin. Cisplatin 37-46 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 33290263-3 2020 We find that Nrf2 is responsible for cisplatin resistance under hypoxia, as Nrf2 knockdown sensitizes HepG2/DDP cells while Nrf2 hyper-activation (though KEAP1 knockdown) increases resistance of HepG2 cells to cisplatin. Cisplatin 37-46 NFE2 like bZIP transcription factor 2 Homo sapiens 76-80 33290263-3 2020 We find that Nrf2 is responsible for cisplatin resistance under hypoxia, as Nrf2 knockdown sensitizes HepG2/DDP cells while Nrf2 hyper-activation (though KEAP1 knockdown) increases resistance of HepG2 cells to cisplatin. Cisplatin 37-46 NFE2 like bZIP transcription factor 2 Homo sapiens 76-80 33290263-3 2020 We find that Nrf2 is responsible for cisplatin resistance under hypoxia, as Nrf2 knockdown sensitizes HepG2/DDP cells while Nrf2 hyper-activation (though KEAP1 knockdown) increases resistance of HepG2 cells to cisplatin. Cisplatin 210-219 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 33066634-0 2020 Carbosilane Dendrimers Loaded with siRNA Targeting Nrf2 as a Tool to Overcome Cisplatin Chemoresistance in Bladder Cancer Cells. Cisplatin 78-87 NFE2 like bZIP transcription factor 2 Homo sapiens 51-55 33489797-8 2020 Results: Metformin was observed to synergistically augment cisplatin-induced cytotoxicity by strongly inhibiting the level of Nrf2, thereby weakening the antioxidant system and detoxification ability of Nrf2 and enhancing ROS-mediated apoptosis in NSCLC. Cisplatin 59-68 NFE2 like bZIP transcription factor 2 Homo sapiens 126-130 33489797-8 2020 Results: Metformin was observed to synergistically augment cisplatin-induced cytotoxicity by strongly inhibiting the level of Nrf2, thereby weakening the antioxidant system and detoxification ability of Nrf2 and enhancing ROS-mediated apoptosis in NSCLC. Cisplatin 59-68 NFE2 like bZIP transcription factor 2 Homo sapiens 203-207 33232319-0 2020 LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1. Cisplatin 28-37 NFE2 like bZIP transcription factor 2 Homo sapiens 79-83 33232319-9 2020 Furthermore, Nrf2 and HO-1 mRNA levels, as critical molecules in the oxidative stress pathway, were inhibited by siRNAs targeting MIR4435-2HG, suggesting that MIR4435-2HG-mediated cisplatin resistance occurs through the Nrf2/HO-1 pathway. Cisplatin 180-189 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 33232319-9 2020 Furthermore, Nrf2 and HO-1 mRNA levels, as critical molecules in the oxidative stress pathway, were inhibited by siRNAs targeting MIR4435-2HG, suggesting that MIR4435-2HG-mediated cisplatin resistance occurs through the Nrf2/HO-1 pathway. Cisplatin 180-189 NFE2 like bZIP transcription factor 2 Homo sapiens 220-224 33290263-5 2020 As a result, Nrf2-dependent transcription counteracts HIF-1alpha degradation under mild hypoxia condition, leading to preferential cisplatin-resistance in HepG2/DDP cells. Cisplatin 131-140 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 33294122-0 2020 The Nrf2/PGC1alpha Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer. Cisplatin 83-92 NFE2 like bZIP transcription factor 2 Homo sapiens 4-8 31983246-0 2020 Thymoquinone and Curcumin combination protects cisplatin-induced Kidney Injury, Nephrotoxicity by attenuating NFkB, KIM-1 and ameliorating Nrf2/HO-1 signaling. Cisplatin 47-56 NFE2 like bZIP transcription factor 2 Homo sapiens 139-143 31983246-11 2020 In summary, Tq + Cur had protective effects on cisplatin-induced nephrotoxicity and renal injury, which could be mediated by up-regulation of survival signals like Akt, Nrf2/HO-1, and attenuation of KIM-1, NFkB. Cisplatin 47-56 NFE2 like bZIP transcription factor 2 Homo sapiens 169-173 32800561-0 2020 Baicalein enhanced cisplatin sensitivity of gastric cancer cells by inducing cell apoptosis and autophagy via Akt/mTOR and Nrf2/Keap 1 pathway. Cisplatin 19-28 NFE2 like bZIP transcription factor 2 Homo sapiens 123-127 33066634-3 2020 Nrf2 mediates the adaptive response which contributes to the resistance to chemotherapeutic pro-oxidant drugs, such as cisplatin (CDDP), in various tumors, including bladder cancers. Cisplatin 119-128 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 33066634-3 2020 Nrf2 mediates the adaptive response which contributes to the resistance to chemotherapeutic pro-oxidant drugs, such as cisplatin (CDDP), in various tumors, including bladder cancers. Cisplatin 130-134 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 33066634-7 2020 This study aimed to evaluate the biological activity of siNrf2 loaded on guanidine-terminated carbosilane dendrimers (GCDs) in overcoming CDDP resistance in bladder cancer cells with a high level of Nrf2. Cisplatin 138-142 NFE2 like bZIP transcription factor 2 Homo sapiens 58-62 33041661-10 2020 Overexpression of Nrf2 resulted in decrease sensitivity to cisplatin. Cisplatin 59-68 NFE2 like bZIP transcription factor 2 Homo sapiens 18-22 32574971-7 2020 The underlying mechanisms of monotropein on alleviating cisplatin-induced AKI were associated with the activation of Nrf2/HO-1 pathway against oxidative stress and the inhibition on NF-kappaB signaling to suppress inflammation as well as the regulation on the expressions of proteins in apoptosis pathway in this renal injury model. Cisplatin 56-65 NFE2 like bZIP transcription factor 2 Homo sapiens 117-121 32945421-0 2020 Panax notoginseng Saponins protect auditory cells against cisplatin-induced ototoxicity by inducing the AKT/Nrf2 signaling-mediated redox pathway. Cisplatin 58-67 NFE2 like bZIP transcription factor 2 Homo sapiens 108-112 32945421-13 2020 These findings suggested that PNS protected auditory cells against ototoxicity induced by cisplatin by activating AKT/Nrf2 signaling. Cisplatin 90-99 NFE2 like bZIP transcription factor 2 Homo sapiens 118-122 32428544-0 2020 Nrf2 activation protects auditory hair cells from cisplatin-induced ototoxicity independent on mitochondrial ROS production. Cisplatin 50-59 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 32428544-5 2020 Here our results showed that cisplatin injury reduced Nrf2 expression and inhibited Nrf2 translocation in HEI-OC1 cells and Nrf2 activator tert-butylhydroquinone (TBHQ) rescued hair cells from cisplatin induced apoptosis by suppressing the total cellular ROS accumulation. Cisplatin 29-38 NFE2 like bZIP transcription factor 2 Homo sapiens 54-58 32428544-5 2020 Here our results showed that cisplatin injury reduced Nrf2 expression and inhibited Nrf2 translocation in HEI-OC1 cells and Nrf2 activator tert-butylhydroquinone (TBHQ) rescued hair cells from cisplatin induced apoptosis by suppressing the total cellular ROS accumulation. Cisplatin 29-38 NFE2 like bZIP transcription factor 2 Homo sapiens 84-88 32428544-5 2020 Here our results showed that cisplatin injury reduced Nrf2 expression and inhibited Nrf2 translocation in HEI-OC1 cells and Nrf2 activator tert-butylhydroquinone (TBHQ) rescued hair cells from cisplatin induced apoptosis by suppressing the total cellular ROS accumulation. Cisplatin 29-38 NFE2 like bZIP transcription factor 2 Homo sapiens 84-88 32428544-6 2020 Moreover, we found that decreased ROS accumulation induced by TBHQ didn"t depend on mitochondrial derived ROS production, indicating that Nrf2 activation alleviated cisplatin induced oxidative stress and apoptosis through mitochondrial-independent ROS production. Cisplatin 165-174 NFE2 like bZIP transcription factor 2 Homo sapiens 138-142 32428544-7 2020 Therefore, we provide a potential strategy of prevention and treatment for cisplatin-induced ototoxicity by Nrf2 activation. Cisplatin 75-84 NFE2 like bZIP transcription factor 2 Homo sapiens 108-112 32428544-8 2020 In conclusion, Nrf2 activation protects auditory hair cells from cisplatin-induced ototoxicity through suppressing the total cellular ROS levels which arise from sources other than mitochondria. Cisplatin 65-74 NFE2 like bZIP transcription factor 2 Homo sapiens 15-19 32927432-3 2020 Here we provide evidence in HepG2 hepatocellular carcinoma cells that metformin sensitizes cisplatin-resistant HepG2 cells (HepG2/DDP) through increasing cellular glycolysis and suppressing Nrf2-dependent transcription. Cisplatin 91-100 NFE2 like bZIP transcription factor 2 Homo sapiens 190-194 32102425-11 2020 Further analysis indicated the relevance of nuclear factor erythroid 2related factor 2/antioxidant response element (Nrf2/ARE) signalling for the favourable effect of PEA-15AA on cisplatin sensitivity. Cisplatin 179-188 NFE2 like bZIP transcription factor 2 Homo sapiens 44-86 32394538-4 2020 This study was conducted to examine the association of Nrf2 expression with tumor response to cisplatin-based chemotherapy. Cisplatin 94-103 NFE2 like bZIP transcription factor 2 Homo sapiens 55-59 32394538-10 2020 Patients with Nrf2 positive and C+/N- tumors were determined to more frequently have an unfavorable response to cisplatin-based chemotherapy than those with Nrf2 negative tumors. Cisplatin 112-121 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 32394538-11 2020 CONCLUSIONS: Cytoplasmic Nrf2 expression might potentially be used to predict poor prognosis and unfavorable response to cisplatin-based chemotherapy in patients with NSCLC. Cisplatin 121-130 NFE2 like bZIP transcription factor 2 Homo sapiens 25-29 30787448-16 2020 COMMD10 may play a tumor suppressive role in renal clear cell carcinoma through the miR-590-3p-COMMD10-Cul2-RBX1-NF-kappaB/HIF/NRF2 pathway and regulate the chemotherapy resistance of various tumor cells to cisplatin. Cisplatin 207-216 NFE2 like bZIP transcription factor 2 Homo sapiens 127-131 31583720-7 2020 The cisplatin-R group exhibited lower levels of UCA1 and NRF2 expression but a higher level of miR-495 expression than the cisplatin-S group. Cisplatin 4-13 NFE2 like bZIP transcription factor 2 Homo sapiens 57-61 31583720-12 2020 We suggested for the first time that high expression of UCA1 contributed to the development of chemoresistance to cisplatin through the UCA1/miR-495/NRF2 signaling pathway. Cisplatin 114-123 NFE2 like bZIP transcription factor 2 Homo sapiens 149-153 32814771-10 2020 On the other hand, silencing of Nrf2 expression rendered EpCAMhigh populations sensitive to cisplatin treatment accompanied by the inhibition of colony formation, sphere formation, and invasion efficiency and increased ROS activity. Cisplatin 92-101 NFE2 like bZIP transcription factor 2 Homo sapiens 32-36 32814771-12 2020 Silencing of p62 expression in EpCAMhigh populations resulted in the attenuation of Nrf2 pathway activation suggesting that Nrf2 pathway activation promoted resistance to cisplatin in EpCAMhigh populations. Cisplatin 171-180 NFE2 like bZIP transcription factor 2 Homo sapiens 124-128 32817372-7 2020 In parallel with decreased GULP1 expression, we observed increased expression of NRF2, HMOX1, and other candidate antioxidant genes in cisplatin-resistant cells. Cisplatin 135-144 NFE2 like bZIP transcription factor 2 Homo sapiens 81-85 32088177-6 2020 Meanwhile, BDMC counteracts oxidative stress by inhibiting cisplatin-induced down-regulation of nuclear factor erythroid-2-related factor 2 (Nrf2). Cisplatin 59-68 NFE2 like bZIP transcription factor 2 Homo sapiens 96-139 32088177-6 2020 Meanwhile, BDMC counteracts oxidative stress by inhibiting cisplatin-induced down-regulation of nuclear factor erythroid-2-related factor 2 (Nrf2). Cisplatin 59-68 NFE2 like bZIP transcription factor 2 Homo sapiens 141-145 32092292-5 2020 The initial inhibition of TXNRD1 in the kidney resulted from cisplatin-induced transcriptional activation of Nrf2-regulated genes including Txnrd1. Cisplatin 61-70 NFE2 like bZIP transcription factor 2 Homo sapiens 109-113 32206093-0 2020 Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer. Cisplatin 80-89 NFE2 like bZIP transcription factor 2 Homo sapiens 50-54 32012470-0 2020 MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma. Cisplatin 49-58 NFE2 like bZIP transcription factor 2 Homo sapiens 74-79 32012470-11 2020 Furthermore, inhibition of Nrf-2 also decreased cell proliferation and increased the sensitivity of Eca109 cells to cisplatin. Cisplatin 116-125 NFE2 like bZIP transcription factor 2 Homo sapiens 27-32 32012470-13 2020 CONCLUSION: MiR-153-3p inhibits cell proliferation and confers cisplatin resistance by downregulating Nrf-2 expression in Eca-109 cells. Cisplatin 63-72 NFE2 like bZIP transcription factor 2 Homo sapiens 102-107 32012470-14 2020 Thus, miR-153-3p/Nrf-2 may play an important role in conferring cisplatin resistance in ESCC. Cisplatin 64-73 NFE2 like bZIP transcription factor 2 Homo sapiens 17-22 32102425-11 2020 Further analysis indicated the relevance of nuclear factor erythroid 2related factor 2/antioxidant response element (Nrf2/ARE) signalling for the favourable effect of PEA-15AA on cisplatin sensitivity. Cisplatin 179-188 NFE2 like bZIP transcription factor 2 Homo sapiens 117-121 31791583-0 2020 MBNL1 regulates resistance of HeLa cells to cisplatin via Nrf2. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 58-62 31791583-4 2020 Based on sequencing data mining, we predicted that MBNL1 might be involved in the occurrence and poor prognosis of cervical cancer, and verifed that MBNL1 could regulate the resistance of HeLa cells to cisplatin via Nrf2. Cisplatin 202-211 NFE2 like bZIP transcription factor 2 Homo sapiens 216-220 31815138-0 2019 Sirt5 Attenuates Cisplatin-Induced Acute Kidney Injury through Regulation of Nrf2/HO-1 and Bcl-2. Cisplatin 17-26 NFE2 like bZIP transcription factor 2 Homo sapiens 77-81 31974389-6 2020 Curcumin exerts permissive and chemosensitive properties by targeting the cisplatin chemoresistant factors Nrf-2, NF-kappaB and STAT-3 phosphorylation. Cisplatin 74-83 NFE2 like bZIP transcription factor 2 Homo sapiens 107-112 31897145-0 2020 Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway. Cisplatin 26-35 NFE2 like bZIP transcription factor 2 Homo sapiens 116-120 31897145-5 2020 CDDP-mediated NF-E2 related factor 2 (Nrf2)/light chain of System xc - (xCT) pathway activation was associated with the resistance of cells to CDDP. Cisplatin 0-4 NFE2 like bZIP transcription factor 2 Homo sapiens 14-36 31897145-5 2020 CDDP-mediated NF-E2 related factor 2 (Nrf2)/light chain of System xc - (xCT) pathway activation was associated with the resistance of cells to CDDP. Cisplatin 0-4 NFE2 like bZIP transcription factor 2 Homo sapiens 38-42 31897145-5 2020 CDDP-mediated NF-E2 related factor 2 (Nrf2)/light chain of System xc - (xCT) pathway activation was associated with the resistance of cells to CDDP. Cisplatin 143-147 NFE2 like bZIP transcription factor 2 Homo sapiens 14-36 31897145-5 2020 CDDP-mediated NF-E2 related factor 2 (Nrf2)/light chain of System xc - (xCT) pathway activation was associated with the resistance of cells to CDDP. Cisplatin 143-147 NFE2 like bZIP transcription factor 2 Homo sapiens 38-42 31897145-6 2020 Therefore, erastin/sorafenib regulation of Nrf2 or xCT expression may alter the sensitivity of tumour cells to CDDP. Cisplatin 111-115 NFE2 like bZIP transcription factor 2 Homo sapiens 43-47 31776385-0 2019 The balance between NRF2/GSH antioxidant mediated pathway and DNA repair modulates cisplatin resistance in lung cancer cells. Cisplatin 83-92 NFE2 like bZIP transcription factor 2 Homo sapiens 20-24 31776385-6 2019 Also, we noted that glutathione intracellular levels, and expression and activity of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) were determinant for cisplatin cytotoxicity. Cisplatin 182-191 NFE2 like bZIP transcription factor 2 Homo sapiens 110-153 31776385-6 2019 Also, we noted that glutathione intracellular levels, and expression and activity of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) were determinant for cisplatin cytotoxicity. Cisplatin 182-191 NFE2 like bZIP transcription factor 2 Homo sapiens 155-159 31776385-8 2019 Thus, the results indicate that NRF2 and glutathione levels figure as important cisplatin resistance biomarkers in lung cancer. Cisplatin 80-89 NFE2 like bZIP transcription factor 2 Homo sapiens 32-36 31877176-0 2019 alpha-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway. Cisplatin 35-44 NFE2 like bZIP transcription factor 2 Homo sapiens 80-84 31659617-8 2019 And O-GSP can modulate the decrease of Nrf2 and HO-1 expression induced by cisplatin, and improve the cisplatin-induced activity and apoptosis rate of cells by stimulating the expression of HO-1. Cisplatin 75-84 NFE2 like bZIP transcription factor 2 Homo sapiens 39-43 31815138-12 2019 The levels of Nrf2, HO-1, and Bcl-2 proteins in HK-2 cells were also decreased after CDDP treatment. Cisplatin 85-89 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 31815138-13 2019 Moreover, Nrf2 and Bcl-2 siRNA partly abolished the protecting effect of Sirt5 on CDDP-induced apoptosis and cytochrome c release. Cisplatin 82-86 NFE2 like bZIP transcription factor 2 Homo sapiens 10-14 31815138-15 2019 Together, the results demonstrated that Sirt5 attenuated cisplatin-induced apoptosis and mitochondrial injury in human kidney HK-2 cells, possibly through the regulation of Nrf2/HO-1 and Bcl-2. Cisplatin 57-66 NFE2 like bZIP transcription factor 2 Homo sapiens 173-177 31472965-13 2019 Conversely, when Nrf2 was knocked down in cisplatin-resistant ovarian cancer cells, CD99 expression and cell viability with cisplatin treatment decreased, while simultaneously upregulating CD99 reactivated cisplatin resistance in ovarian cancer cells. Cisplatin 42-51 NFE2 like bZIP transcription factor 2 Homo sapiens 17-21 30811078-0 2019 The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin. Cisplatin 118-127 NFE2 like bZIP transcription factor 2 Homo sapiens 48-52 30811078-7 2019 Western blotting analysis indicated that protein levels of p-STAT3 (Ser727), nuclear factor erythroid 2-related factor 2 (Nrf2), and glutathione peroxidase 4 (GPx4) in drug-resistant strains increased significantly in response to cisplatin. Cisplatin 230-239 NFE2 like bZIP transcription factor 2 Homo sapiens 77-120 30811078-10 2019 The reduction of protein levels of p-STAT3 (Ser727), Nrf2, and GPx4 in MG63/DDP and Saos-2/DDP cells resulted in increased ferroptosis and sensitivity to cisplatin. Cisplatin 154-163 NFE2 like bZIP transcription factor 2 Homo sapiens 53-57 31472965-13 2019 Conversely, when Nrf2 was knocked down in cisplatin-resistant ovarian cancer cells, CD99 expression and cell viability with cisplatin treatment decreased, while simultaneously upregulating CD99 reactivated cisplatin resistance in ovarian cancer cells. Cisplatin 124-133 NFE2 like bZIP transcription factor 2 Homo sapiens 17-21 31472965-13 2019 Conversely, when Nrf2 was knocked down in cisplatin-resistant ovarian cancer cells, CD99 expression and cell viability with cisplatin treatment decreased, while simultaneously upregulating CD99 reactivated cisplatin resistance in ovarian cancer cells. Cisplatin 124-133 NFE2 like bZIP transcription factor 2 Homo sapiens 17-21 31472965-15 2019 In conclusion, Nrf2 induced cisplatin resistance in ovarian cancer cells by promoting CD99 expression. Cisplatin 28-37 NFE2 like bZIP transcription factor 2 Homo sapiens 15-19 31456942-0 2019 SIRT5 Promotes Cisplatin Resistance in Ovarian Cancer by Suppressing DNA Damage in a ROS-Dependent Manner via Regulation of the Nrf2/HO-1 Pathway. Cisplatin 15-24 NFE2 like bZIP transcription factor 2 Homo sapiens 128-132 31472965-0 2019 Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression. Cisplatin 13-22 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 31472965-3 2019 This research was performed to explore the role of Nrf2 (nuclear factor, erythroid 2 like 2) and CD99 (CD99 molecule) in cisplatin resistance in ovarian cancer. Cisplatin 121-130 NFE2 like bZIP transcription factor 2 Homo sapiens 51-91 31472965-11 2019 It was also found that when Nrf2 was upregulated in cisplatin-sensitive ovarian cells, CD99 expression and cell viability increased after cisplatin treatment. Cisplatin 52-61 NFE2 like bZIP transcription factor 2 Homo sapiens 28-32 31472965-11 2019 It was also found that when Nrf2 was upregulated in cisplatin-sensitive ovarian cells, CD99 expression and cell viability increased after cisplatin treatment. Cisplatin 138-147 NFE2 like bZIP transcription factor 2 Homo sapiens 28-32 31472965-12 2019 Knockdown of CD99 could reverse cisplatin resistance induced by Nrf2. Cisplatin 32-41 NFE2 like bZIP transcription factor 2 Homo sapiens 64-68 31288066-5 2019 Therefore, the aim of this work was to investigate molecular mechanism of RA and cisplatin co-treatment in A549 cells, focusing in NRF2 pathway. Cisplatin 81-90 NFE2 like bZIP transcription factor 2 Homo sapiens 131-135 31495720-0 2019 Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. Cisplatin 25-34 NFE2 like bZIP transcription factor 2 Homo sapiens 89-93 31495720-11 2019 Although Scribble deficiency tends to lead to cisplatin resistance by Nox2/ROS and Nrf2/PD-L1, it is still possible that Scribble deficiency-induced PD-L1 may yield benefits in immunotherapy. Cisplatin 46-55 NFE2 like bZIP transcription factor 2 Homo sapiens 83-87 31456942-6 2019 Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Cisplatin 51-60 NFE2 like bZIP transcription factor 2 Homo sapiens 208-251 31456942-6 2019 Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Cisplatin 51-60 NFE2 like bZIP transcription factor 2 Homo sapiens 253-257 31456942-6 2019 Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Cisplatin 105-114 NFE2 like bZIP transcription factor 2 Homo sapiens 208-251 31456942-6 2019 Mechanistically, we show that SIRT5 contributes to cisplatin resistance in ovarian cancer by suppressing cisplatin-induced DNA damage in a reactive oxygen species (ROS)-dependent manner via regulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway. Cisplatin 105-114 NFE2 like bZIP transcription factor 2 Homo sapiens 253-257 31287493-0 2019 LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2. Cisplatin 21-30 NFE2 like bZIP transcription factor 2 Homo sapiens 100-104 31135681-13 2019 CONCLUSION: Our results suggest that EPO alleviates cisplatin-induced ototoxicity by activating Nrf2-ARE signaling. Cisplatin 52-61 NFE2 like bZIP transcription factor 2 Homo sapiens 96-100 30542710-0 2018 miR-144-3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2. Cisplatin 54-63 NFE2 like bZIP transcription factor 2 Homo sapiens 77-81 31056260-0 2019 Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 57-61 31056260-8 2019 Additionally, through combination with CDDP, OST dose- and time-dependently reduced NRF2 expression in CDDP-resistant cervical cancer cells. Cisplatin 39-43 NFE2 like bZIP transcription factor 2 Homo sapiens 84-88 31056260-8 2019 Additionally, through combination with CDDP, OST dose- and time-dependently reduced NRF2 expression in CDDP-resistant cervical cancer cells. Cisplatin 103-107 NFE2 like bZIP transcription factor 2 Homo sapiens 84-88 31056260-10 2019 Importantly, CDDP combined with LY294002, inhibitor of phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) signaling, markedly decreased the expression of NRF2, HO-1, NQO1 and GCLC in drug-resistant cervical cancer cells. Cisplatin 13-17 NFE2 like bZIP transcription factor 2 Homo sapiens 170-174 31056260-12 2019 Taken together, these findings indicated that OST could be used as a potential sensitizer to reverse chemoresistance of cisplatin-resistant cervical cancer to cisplatin through repressing NRF2 expression partly associated with PI3K/AKT blockage. Cisplatin 120-129 NFE2 like bZIP transcription factor 2 Homo sapiens 188-192 31056260-12 2019 Taken together, these findings indicated that OST could be used as a potential sensitizer to reverse chemoresistance of cisplatin-resistant cervical cancer to cisplatin through repressing NRF2 expression partly associated with PI3K/AKT blockage. Cisplatin 159-168 NFE2 like bZIP transcription factor 2 Homo sapiens 188-192 30668336-0 2019 Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression. Cisplatin 49-58 NFE2 like bZIP transcription factor 2 Homo sapiens 117-121 30668336-3 2019 The cisplatin (CDDP) resistance is accompanied by an increase in Nrf2 protein expression which contributes to conferring resistance. Cisplatin 4-13 NFE2 like bZIP transcription factor 2 Homo sapiens 65-69 30668336-3 2019 The cisplatin (CDDP) resistance is accompanied by an increase in Nrf2 protein expression which contributes to conferring resistance. Cisplatin 15-19 NFE2 like bZIP transcription factor 2 Homo sapiens 65-69 30668336-21 2019 Its high effectiveness in CDDP resistant cells could be related to the inhibition of Nrf2, YAP, and c-Myc expressions. Cisplatin 26-30 NFE2 like bZIP transcription factor 2 Homo sapiens 85-89 31223046-0 2019 p62/SQSTM1 protects against cisplatin-induced oxidative stress in kidneys by mediating the cross talk between autophagy and the Keap1-Nrf2 signalling pathway. Cisplatin 28-37 NFE2 like bZIP transcription factor 2 Homo sapiens 134-138 31223046-8 2019 To explore the cross talk between p62 and the Keap1-Nrf2 signalling pathway, HK-2 cells were transfected with siRNA targeting Nrf2, and we found that Nrf2 knockdown significantly reduced cisplatin-induced p62 expression. Cisplatin 187-196 NFE2 like bZIP transcription factor 2 Homo sapiens 52-56 31223046-8 2019 To explore the cross talk between p62 and the Keap1-Nrf2 signalling pathway, HK-2 cells were transfected with siRNA targeting Nrf2, and we found that Nrf2 knockdown significantly reduced cisplatin-induced p62 expression. Cisplatin 187-196 NFE2 like bZIP transcription factor 2 Homo sapiens 126-130 31223046-8 2019 To explore the cross talk between p62 and the Keap1-Nrf2 signalling pathway, HK-2 cells were transfected with siRNA targeting Nrf2, and we found that Nrf2 knockdown significantly reduced cisplatin-induced p62 expression. Cisplatin 187-196 NFE2 like bZIP transcription factor 2 Homo sapiens 126-130 31293646-0 2019 Nuclear Nrf2 Activity in Laryngeal Carcinoma is Regulated by SENP3 After Cisplatin-Induced Reactive Oxygen Species Stress. Cisplatin 73-82 NFE2 like bZIP transcription factor 2 Homo sapiens 8-12 31293646-5 2019 Silencing of Nrf2 in laryngeal carcinoma cell line Hep-2 significantly reduced cell viability and enhanced apoptosis rates under cisplatin, 5-fluorouracil (5-FU) and phenethyl isothiocyanate (PEITC) exposure. Cisplatin 129-138 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 31293646-6 2019 Cisplatin exposure induced ROS stress in Hep-2 cells in a time-dependent manner and was accompanied by increased Nrf2 and SENP3 protein accumulations, an effect reversed by the addition of the antioxidant N-acetyl-cysteine (NAC). Cisplatin 0-9 NFE2 like bZIP transcription factor 2 Homo sapiens 113-117 31293646-9 2019 Our data identified intranuclear activation of Nrf2 is triggered by cisplatin-induced ROS development through the activity of SENP3. Cisplatin 68-77 NFE2 like bZIP transcription factor 2 Homo sapiens 47-51 30030687-0 2019 NRAL mediates cisplatin resistance in hepatocellular carcinoma via miR-340-5p/Nrf2 axis. Cisplatin 14-23 NFE2 like bZIP transcription factor 2 Homo sapiens 78-82 30030687-4 2019 A novel lncRNA, termed NRAL (Nrf2 regulation-associated lncRNA), was identified, and the initial results indicated that it was highly expressed in HepG2 cisplatin resistant cell lines compared to their parental counterparts. Cisplatin 153-162 NFE2 like bZIP transcription factor 2 Homo sapiens 29-33 30030687-6 2019 Mechanistically, the results indicated that NRAL regulates Nrf2 expression through miR-340-5p serving as a competing endogenous RNA (ceRNA), thus influencing the CDDP-induced phenotype in HCC. Cisplatin 162-166 NFE2 like bZIP transcription factor 2 Homo sapiens 59-63 30030687-7 2019 Collectively, the present investigation suggest that the NRAL/miR-340-5p/Nrf2 axis mediates cisplatin resistance in HCC, which may provide novel targets for overcoming cisplatin resistance in hepatocellular carcinoma cells. Cisplatin 92-101 NFE2 like bZIP transcription factor 2 Homo sapiens 73-77 30030687-7 2019 Collectively, the present investigation suggest that the NRAL/miR-340-5p/Nrf2 axis mediates cisplatin resistance in HCC, which may provide novel targets for overcoming cisplatin resistance in hepatocellular carcinoma cells. Cisplatin 168-177 NFE2 like bZIP transcription factor 2 Homo sapiens 73-77 30542710-3 2018 In the course of the study, we unexpectedly found that miR-144-3p could regulate the cisplatin resistance of lung cancer cells via Nrf2. Cisplatin 85-94 NFE2 like bZIP transcription factor 2 Homo sapiens 131-135 30112565-13 2018 These results suggest that WGS may reverse cDDP resistance in SGC7901/cDDP cells through blocking the PI3K/Akt/Nrf2/ARE signaling pathway, thus enhancing the cytotoxicity of cDDP and inducing oxidative stress reaction and apoptosis. Cisplatin 43-47 NFE2 like bZIP transcription factor 2 Homo sapiens 111-115 29857117-10 2018 Specifically, Nrf2 plays an indispensable role in NSCLC cell sensitivity to platinum-based treatments and we found that combination of CP-673451 and cisplatin produced a synergistic anticancer effect and substantial ROS production in vitro. Cisplatin 149-158 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 29212168-0 2017 Nrf2 induces cisplatin resistance via suppressing the iron export related gene SLC40A1 in ovarian cancer cells. Cisplatin 13-22 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 29906742-0 2018 Xanthohumol attenuates cisplatin-induced nephrotoxicity through inhibiting NF-kappaB and activating Nrf2 signaling pathways. Cisplatin 23-32 NFE2 like bZIP transcription factor 2 Homo sapiens 100-104 29752286-5 2018 RNA sequencing data indicate that cisplatin triggers a systemic stress response, in which DAF-16/FOXO and SKN-1/NRF2, two conserved transcription factors, are key regulators. Cisplatin 34-43 NFE2 like bZIP transcription factor 2 Homo sapiens 112-116 29967581-7 2018 Mangiferin was found to ameliorate cisplatin induced nephrotoxicity in vitro and in vivo by attenuating the induction of oxidative stress and upregulating Nrf-2 mediated pro-survival signaling cascades via the activation of PI3K. Cisplatin 35-44 NFE2 like bZIP transcription factor 2 Homo sapiens 155-160 29110908-0 2017 Corrigendum to "MicroRNA-140-5p attenuated oxidative stress in Cisplatin induced acute kidney injury by activating Nrf2/ARE pathway through a Keap1-independent mechanism" [Exp. Cisplatin 63-72 NFE2 like bZIP transcription factor 2 Homo sapiens 115-119 27457817-0 2017 Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin. Cisplatin 125-134 NFE2 like bZIP transcription factor 2 Homo sapiens 29-35 27457817-7 2017 The NFE2L2 promotor variant rs6721961 may therefore be protective against hearing loss in cisplatin-receiving cancer patients. Cisplatin 90-99 NFE2 like bZIP transcription factor 2 Homo sapiens 4-10 28767070-0 2017 Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. Cisplatin 119-128 NFE2 like bZIP transcription factor 2 Homo sapiens 31-46 29621903-6 2018 Furthermore, abrogation of Nrf2 significantly increased the sensitivity of K-rasG12V cells to multiple anticancer agents including phenethyl isothiocyanate (PEITC), doxorubicin, etoposide, and cisplatin. Cisplatin 193-202 NFE2 like bZIP transcription factor 2 Homo sapiens 27-31 29518609-8 2018 KEY FINDINGS: Cytotoxicity of cisplatin (Cis) in KKU-100 cells was enhanced by knockdown of Nrf2 expression. Cisplatin 30-39 NFE2 like bZIP transcription factor 2 Homo sapiens 92-96 29061583-6 2018 In addition, recombinant NRF2-siRNA was effective to sensitize both 143B and MG63 cells to doxorubicin, cisplatin, and sorafenib, which was associated with significant downregulation of NRF2-targeted ATP-binding cassette (ABC) efflux transporters (ABCC3, ABCC4, and ABCG2). Cisplatin 104-113 NFE2 like bZIP transcription factor 2 Homo sapiens 25-29 29061583-6 2018 In addition, recombinant NRF2-siRNA was effective to sensitize both 143B and MG63 cells to doxorubicin, cisplatin, and sorafenib, which was associated with significant downregulation of NRF2-targeted ATP-binding cassette (ABC) efflux transporters (ABCC3, ABCC4, and ABCG2). Cisplatin 104-113 NFE2 like bZIP transcription factor 2 Homo sapiens 186-190 29212168-1 2017 Induction of Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) has been demonstrated to be involved in cisplatin resistance in ovarian cancer. Cisplatin 112-121 NFE2 like bZIP transcription factor 2 Homo sapiens 66-70 29212168-4 2017 Elevated level of Nrf2 and reduced level of SLC40A1 were found in cisplatin-resistant ovarian cancer cells as compared with cisplatin-sensitive ovarian cancer cells. Cisplatin 66-75 NFE2 like bZIP transcription factor 2 Homo sapiens 18-22 29212168-4 2017 Elevated level of Nrf2 and reduced level of SLC40A1 were found in cisplatin-resistant ovarian cancer cells as compared with cisplatin-sensitive ovarian cancer cells. Cisplatin 124-133 NFE2 like bZIP transcription factor 2 Homo sapiens 18-22 29212168-8 2017 Overexpression of SLC40A1 was able to reverse cisplatin resistance induced by Nrf2, while knockdown of SLC40A1 restored cisplatin resistance and increased iron concentration. Cisplatin 46-55 NFE2 like bZIP transcription factor 2 Homo sapiens 78-82 27544755-0 2016 Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer. Cisplatin 38-47 NFE2 like bZIP transcription factor 2 Homo sapiens 10-14 28767070-0 2017 Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines. Cisplatin 119-128 NFE2 like bZIP transcription factor 2 Homo sapiens 74-78 28767070-9 2017 NRF2 knockdown resulted in downregulation of cytoprotective enzymes and resensitised 3/4 LTTs towards cisplatin as demonstrated by reduced IC50 values, increased gammaH2AX foci formation, and elevated number of apoptotic cells. Cisplatin 102-111 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 28767070-10 2017 In conclusion, while LTT lines displayed diversity in NRF2 activation, NRF2 signalling contributed to cisplatin resistance in LTT lines, albeit in diverse ways. Cisplatin 102-111 NFE2 like bZIP transcription factor 2 Homo sapiens 71-75 28767070-11 2017 Accordingly, inhibition of NRF2 can be used to resensitise UC cells to cisplatin, but responses in patients may likewise be variable. Cisplatin 71-80 NFE2 like bZIP transcription factor 2 Homo sapiens 27-31 28112439-0 2017 ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. Cisplatin 43-52 NFE2 like bZIP transcription factor 2 Homo sapiens 10-14 28112439-1 2017 Previously, we have demonstrated that NRF2 plays a key role in mediating cisplatin resistance in ovarian cancer. Cisplatin 73-82 NFE2 like bZIP transcription factor 2 Homo sapiens 38-42 28112439-2 2017 To further explore the mechanism underlying NRF2-dependent cisplatin resistance, we stably overexpressed or knocked down NRF2 in parental and cisplatin-resistant human ovarian cancer cells, respectively. Cisplatin 59-68 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 28112439-6 2017 Next, we investigated the contribution of ABCF2 in NRF2-mediated cisplatin resistance using our stable ovarian cancer cell lines. Cisplatin 65-74 NFE2 like bZIP transcription factor 2 Homo sapiens 51-55 28112439-7 2017 The NRF2-overexpressing cell line, containing high levels of ABCF2, was more resistant to cisplatin-induced apoptosis compared to its control cell line; whereas the NRF2 knockdown cell line with low levels of ABCF2, was more sensitive to cisplatin treatment than its control cell line. Cisplatin 90-99 NFE2 like bZIP transcription factor 2 Homo sapiens 4-8 28112439-7 2017 The NRF2-overexpressing cell line, containing high levels of ABCF2, was more resistant to cisplatin-induced apoptosis compared to its control cell line; whereas the NRF2 knockdown cell line with low levels of ABCF2, was more sensitive to cisplatin treatment than its control cell line. Cisplatin 238-247 NFE2 like bZIP transcription factor 2 Homo sapiens 4-8 28112439-10 2017 This data indicate that the novel NRF2 target gene, ABCF2, plays a critical role in cisplatin resistance in ovarian cancer, and that targeting ABCF2 may be a new strategy to improve chemotherapeutic efficiency. Cisplatin 84-93 NFE2 like bZIP transcription factor 2 Homo sapiens 34-38 28120035-5 2017 Nrf2 knockdowns exhibited marked increases in mitochondrial membrane depolarization and ROS production following cisplatin treatment, with the cervical ME180R knockdowns exhibiting the greatest effect (AKR1C1 and AKR1C2 levels were decreased in the ME180R and SKOV3 cells to near zero). Cisplatin 113-122 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 28120035-10 2017 CONCLUSIONS: Nrf2 controls a multitude of different candidate genes; however, it did markedly modulate cisplatin resistance through the AKR family. Cisplatin 103-112 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 27544755-8 2016 It inhibited nuclear factor erythroid 2-related factor 2 and glutathione S-transferase P in cisplatin-resistant HNC cells, resulting in increased ROS accumulation in HNC cells, an effect that could be blocked by the antioxidant N-acetyl-L-cysteine. Cisplatin 92-101 NFE2 like bZIP transcription factor 2 Homo sapiens 13-56 27616468-9 2016 It alleviated renal oxidative stress due to cisplatin by lowering lipid peroxides, nitric oxide and Nrf2 levels with concomitant enhancement of GSH and GPx. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 100-104 27822011-0 2016 Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway. Cisplatin 24-33 NFE2 like bZIP transcription factor 2 Homo sapiens 88-92 27822011-0 2016 Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway. Cisplatin 63-72 NFE2 like bZIP transcription factor 2 Homo sapiens 88-92 27822011-12 2016 CONCLUSION: The results confirmed the sensibilization of UA on HepG2/DDP cells to cisplatin, which was possibly mediated via the Nrf2/antioxidant response element pathway. Cisplatin 82-91 NFE2 like bZIP transcription factor 2 Homo sapiens 129-133 27601007-6 2016 The reactive degree of NRF2 signaling also varies between nedaplatin and cisplatin. Cisplatin 73-82 NFE2 like bZIP transcription factor 2 Homo sapiens 23-27 27480280-3 2016 We aimed to evaluate the ability of short-term treatment with the Nrf2 activator bardoxolone methyl (CDDO-Me) to protect against cisplatin-induced kidney cell toxicity. Cisplatin 129-138 NFE2 like bZIP transcription factor 2 Homo sapiens 66-70 26536456-10 2015 While antioxidant EGCG showed chemosensitization of MDA-MB231 cells to cisplatin by activating Nrf2-ARE signaling, PTS, another antioxidant showed chemoprotection. Cisplatin 71-80 NFE2 like bZIP transcription factor 2 Homo sapiens 95-99 26801320-4 2016 Furthermore, the HO-1 expression induced by cisplatin was strongly inhibited by the knockdown of nuclear factor-erythroid-2-related factor-2 (Nrf-2), and the oxidative damages induced by cisplatin were significantly enhanced. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 97-140 26801320-4 2016 Furthermore, the HO-1 expression induced by cisplatin was strongly inhibited by the knockdown of nuclear factor-erythroid-2-related factor-2 (Nrf-2), and the oxidative damages induced by cisplatin were significantly enhanced. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 142-147 26801320-5 2016 Therefore, it may be concluded that the inhibition of HO-1 or the knockdown of Nrf-2 significantly enhanced cisplatin"s anticancer effects on Hep-2 cells. Cisplatin 108-117 NFE2 like bZIP transcription factor 2 Homo sapiens 79-84 28959534-3 2016 The purpose of this study was to determine whether the Nrf2 activators oltipraz, sulforaphane, and oleanolic acid could protect human kidney cells against cisplatin-induced injury and to compare the protective effects between three Nrf2 activators. Cisplatin 155-164 NFE2 like bZIP transcription factor 2 Homo sapiens 55-59 28959534-8 2016 These findings suggest potential human kidney protective benefits of Nrf2 activators with planned exposures to cisplatin. Cisplatin 111-120 NFE2 like bZIP transcription factor 2 Homo sapiens 69-73 26573721-0 2016 Vanadium(III)-L-cysteine protects cisplatin-induced nephropathy through activation of Nrf2/HO-1 pathway. Cisplatin 34-43 NFE2 like bZIP transcription factor 2 Homo sapiens 86-90 25450742-7 2015 Cisplatin affected several pathways including, p53 signalling, Nrf2 mediated oxidative stress response, mitochondrial processes, mTOR and AMPK signalling. Cisplatin 0-9 NFE2 like bZIP transcription factor 2 Homo sapiens 63-67 26497680-2 2015 Here, we hypothesized that mutant p53 could upregulate Nrf2 expression at the transcriptional level, thereby conferring cisplatin resistance in non-small cell lung cancer (NSCLC). Cisplatin 120-129 NFE2 like bZIP transcription factor 2 Homo sapiens 55-59 26497680-5 2015 The MTT assay indicated that an increase in Nrf2 expression by mutant p53 is responsible for cisplatin resistance. Cisplatin 93-102 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 27602124-7 2016 Cisplatin augmented reactive oxygen species in the MG-63 cells, followed by the translocation of Nrf2 from the cytoplasm into the nucleus, which triggered ARE-driven luciferase expression. Cisplatin 0-9 NFE2 like bZIP transcription factor 2 Homo sapiens 97-101 27015836-5 2016 After knockdown of Nrf2, the sensitivity of those cells to the cytotoxicity of cisplatin (Cis) was enhanced in association with the increased release of AIF and downregulation of Bcl-xl in both cells. Cisplatin 79-88 NFE2 like bZIP transcription factor 2 Homo sapiens 19-23 26193055-7 2015 Erdosteine markedly induces expression of NF-E2-related factor 2 (Nrf2), which may contribute to the increase in expression of glutathione redox genes gamma-l-glutamate-l-cysteine-ligase catalytic and gamma-l-glutamate-l-cysteine-ligase modifier subunits, as well as in the antioxidant genes HO-1 and SOD2 in cisplatin-treated HEI-OC1 cells. Cisplatin 309-318 NFE2 like bZIP transcription factor 2 Homo sapiens 42-64 26193055-7 2015 Erdosteine markedly induces expression of NF-E2-related factor 2 (Nrf2), which may contribute to the increase in expression of glutathione redox genes gamma-l-glutamate-l-cysteine-ligase catalytic and gamma-l-glutamate-l-cysteine-ligase modifier subunits, as well as in the antioxidant genes HO-1 and SOD2 in cisplatin-treated HEI-OC1 cells. Cisplatin 309-318 NFE2 like bZIP transcription factor 2 Homo sapiens 66-70 26193055-10 2015 Thus, our results suggest that treatment with erdosteine is significantly attenuated cisplatin-induced damage through the activation of Nrf2-dependent antioxidant genes, inhibition of pro-inflammatory cytokines, activation of the PI3K/Akt signaling, and mitochondrial-related inhibition of pro-apoptotic protein expression in HEI-OC1 auditory cells. Cisplatin 85-94 NFE2 like bZIP transcription factor 2 Homo sapiens 136-140 25739673-11 2015 CONCLUSIONS: A gene expression signature of NRF2 pathway activation is associated with benefit from adjuvant cisplatin/vinorelbine in SCC. Cisplatin 109-118 NFE2 like bZIP transcription factor 2 Homo sapiens 44-48 26497680-6 2015 Among the Nrf2 downstream genes, Bcl-2 and Bcl-xL contribute more strongly to Nrf2-mediated cisplatin resistance when compared with heme oxygenase 1 (HO-1). Cisplatin 92-101 NFE2 like bZIP transcription factor 2 Homo sapiens 10-14 26497680-6 2015 Among the Nrf2 downstream genes, Bcl-2 and Bcl-xL contribute more strongly to Nrf2-mediated cisplatin resistance when compared with heme oxygenase 1 (HO-1). Cisplatin 92-101 NFE2 like bZIP transcription factor 2 Homo sapiens 78-82 26497680-7 2015 Cox regression analysis showed that patients with high-Nrf2, high-Bcl-2, high-Bcl-xL mRNA tumors were more commonly occurred unfavorable response to cisplatin-based chemotherapy than their counterparts. Cisplatin 149-158 NFE2 like bZIP transcription factor 2 Homo sapiens 55-59 26497680-8 2015 The prognostic significance of Nrf2 mRNA levels on OS and RFS was also observed in patients who have received cisplatin-based chemotherapy, particularly in p53-mutant patients. Cisplatin 110-119 NFE2 like bZIP transcription factor 2 Homo sapiens 31-35 26497680-9 2015 Collectively, mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression, and Nrf2 mRNA level may predict chemotherapeutic response and outcomes in NSCLC. Cisplatin 36-45 NFE2 like bZIP transcription factor 2 Homo sapiens 77-81 26356271-0 2015 Cryptotanshinone Reverses Cisplatin Resistance of Human Lung Carcinoma A549 Cells through Down-Regulating Nrf2 Pathway. Cisplatin 26-35 NFE2 like bZIP transcription factor 2 Homo sapiens 106-110 25843086-0 2015 3",4",5",5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 105-109 25843086-0 2015 3",4",5",5,7-pentamethoxyflavone sensitizes Cisplatin-resistant A549 cells to Cisplatin by inhibition of Nrf2 pathway. Cisplatin 78-87 NFE2 like bZIP transcription factor 2 Homo sapiens 105-109 25843086-3 2015 In this study, we found that the expression levels of Nrf2 and its target genes GCLC, HO-1, NQO1 were significantly higher in cisplatin-resistant A549 (A549/CDDP) cells than those in A549 cells, and this resistance was partially reversed by Nrf2 siRNA. Cisplatin 126-135 NFE2 like bZIP transcription factor 2 Homo sapiens 54-58 25843086-3 2015 In this study, we found that the expression levels of Nrf2 and its target genes GCLC, HO-1, NQO1 were significantly higher in cisplatin-resistant A549 (A549/CDDP) cells than those in A549 cells, and this resistance was partially reversed by Nrf2 siRNA. Cisplatin 126-135 NFE2 like bZIP transcription factor 2 Homo sapiens 241-245 25896339-7 2015 Moreover, Nrf2 knockdown exhibited increased sensitivity to the anticancer drug, cisplatin, presumably by potentiating the oxidative stress induced by cisplatin. Cisplatin 81-90 NFE2 like bZIP transcription factor 2 Homo sapiens 10-14 25896339-7 2015 Moreover, Nrf2 knockdown exhibited increased sensitivity to the anticancer drug, cisplatin, presumably by potentiating the oxidative stress induced by cisplatin. Cisplatin 151-160 NFE2 like bZIP transcription factor 2 Homo sapiens 10-14 26356271-1 2015 BACKGROUND/AIMS: To explore whether Nrf2 was associated with drug-resistance in cisplatin resistant A549 (A549/DDP) cells, and if cryptotanshinone (CTS), one of the bioactive compounds isolated from the roots of Salvia miltiorrhiza Bunge (Danshen), could enhance the sensitivity in A549/DDP cells towards cisplatin. Cisplatin 80-89 NFE2 like bZIP transcription factor 2 Homo sapiens 36-40 26356271-3 2015 RESULTS: The endogenous expression levels of Nrf2 as well as its target genes including GCLC, GCLM, HO-1, NQO1 and MRP1 were much higher in A549/DDP cells than those of A549 cells and the susceptibility of A549/DDP cells to cisplatin was partially restored by silencing Nrf2. Cisplatin 224-233 NFE2 like bZIP transcription factor 2 Homo sapiens 45-49 26356271-4 2015 The combination of CTS and cisplatin led to cell death and apoptosis through sensitizing A549/DDP cells towards cisplatin compared with cisplatin mono-treatment, however, this reversal role could be abolished by Nrf2 knockdown. Cisplatin 27-36 NFE2 like bZIP transcription factor 2 Homo sapiens 212-216 24817946-14 2014 Taken together, Nrf2 signaling may regulate cisplatin resistance by activating autophagy. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 16-20 25269472-0 2014 p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. Cisplatin 26-35 NFE2 like bZIP transcription factor 2 Homo sapiens 91-95 25269472-9 2014 Collectively, our data indicate that cisplatin resistance in HOCCs is partially attributable to their high expression of p62, which plays an important role in preventing ROS stress-induced apoptosis by regulating the Keap1-Nrf2-ARE signaling pathway. Cisplatin 37-46 NFE2 like bZIP transcription factor 2 Homo sapiens 223-227 24817946-0 2014 Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Cisplatin 13-22 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 24837013-0 2014 The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Cisplatin 59-68 NFE2 like bZIP transcription factor 2 Homo sapiens 4-8 24837013-4 2014 We, therefore, investigated whether Nrf2 might regulate cisplatin resistance in bladder cancer. Cisplatin 56-65 NFE2 like bZIP transcription factor 2 Homo sapiens 36-40 24837013-8 2014 Nrf2 expression was greater in RT112-CP cisplatin-resistant cells compared with that in parental RT112 cells. Cisplatin 40-49 NFE2 like bZIP transcription factor 2 Homo sapiens 0-4 24837013-10 2014 Cisplatin resistance was associated with Nrf2 expression, and in RT112-CP cells, its depletion partially restored cisplatin sensitivity. Cisplatin 0-9 NFE2 like bZIP transcription factor 2 Homo sapiens 41-45 24837013-12 2014 Expression of Nrf2 in bladder cancer following radical cystectomy was associated with unfavorable overall (median = 0.65 vs. 2.11 y, P = 0.045), bladder cancer-specific, and recurrence-free survival in those patients who also received neoadjuvant cisplatin-based chemotherapy but not in those treated with cystectomy alone. Cisplatin 247-256 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 24837013-13 2014 CONCLUSIONS: Nrf2 overexpression in bladder cancer is associated with clinically relevant cisplatin resistance that is reversible in experimental models and should now be tested in prospective studies. Cisplatin 90-99 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 24817946-3 2014 However, the underlying mechanism by which Nrf2 mediates cisplatin chemoresistance is unclear. Cisplatin 57-66 NFE2 like bZIP transcription factor 2 Homo sapiens 43-47 24817946-11 2014 Knocking down Nrf2 sensitized A2780cp cells to cisplatin treatment and decreased autophagy-related genes, Atg3, Atg6, Atg12 and p62 in both mRNA and protein levels. Cisplatin 47-56 NFE2 like bZIP transcription factor 2 Homo sapiens 14-18 24817946-15 2014 CONCLUSIONS: Nrf2-activated autophagy may function as a novel mechanism causing cisplatin-resistance. Cisplatin 80-89 NFE2 like bZIP transcription factor 2 Homo sapiens 13-17 23749887-5 2013 RESULTS: In vitro, acetaminophen enhanced apoptosis induced by cisplatin and paclitaxel with similar effects on glutathione, reactive oxygen species and mitochondrial membrane potential, but different effects on nuclear factor erythroid 2-related factor 2 (NRF2) translocation. Cisplatin 63-72 NFE2 like bZIP transcription factor 2 Homo sapiens 257-261 25556489-0 2014 miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway. Cisplatin 17-26 NFE2 like bZIP transcription factor 2 Homo sapiens 90-94 25556489-4 2014 In present study, by taking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, it has been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/ CDDP (cisplatin) cells, compared with parental HepG2 cells. Cisplatin 121-130 NFE2 like bZIP transcription factor 2 Homo sapiens 211-215 25556489-4 2014 In present study, by taking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, it has been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/ CDDP (cisplatin) cells, compared with parental HepG2 cells. Cisplatin 242-246 NFE2 like bZIP transcription factor 2 Homo sapiens 211-215 25556489-4 2014 In present study, by taking advantage of miRNA effects on the resistance of human hepatocellular carcinoma cells line to cisplatin, it has been demonstrated that miR-340 were significantly downregulated whereas Nrf2 was upregulated in HepG2/ CDDP (cisplatin) cells, compared with parental HepG2 cells. Cisplatin 248-257 NFE2 like bZIP transcription factor 2 Homo sapiens 211-215 25556489-5 2014 Bioinformatics analysis and luciferase assays of Nrf2-3"-untranslated region-based reporter constructor indicated that Nrf2 was the direct target gene of miR- 340, miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/ CDDP cells to cisplatin. Cisplatin 266-270 NFE2 like bZIP transcription factor 2 Homo sapiens 49-53 25556489-5 2014 Bioinformatics analysis and luciferase assays of Nrf2-3"-untranslated region-based reporter constructor indicated that Nrf2 was the direct target gene of miR- 340, miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/ CDDP cells to cisplatin. Cisplatin 266-270 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 25556489-5 2014 Bioinformatics analysis and luciferase assays of Nrf2-3"-untranslated region-based reporter constructor indicated that Nrf2 was the direct target gene of miR- 340, miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/ CDDP cells to cisplatin. Cisplatin 266-270 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 25556489-5 2014 Bioinformatics analysis and luciferase assays of Nrf2-3"-untranslated region-based reporter constructor indicated that Nrf2 was the direct target gene of miR- 340, miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/ CDDP cells to cisplatin. Cisplatin 280-289 NFE2 like bZIP transcription factor 2 Homo sapiens 49-53 25556489-5 2014 Bioinformatics analysis and luciferase assays of Nrf2-3"-untranslated region-based reporter constructor indicated that Nrf2 was the direct target gene of miR- 340, miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/ CDDP cells to cisplatin. Cisplatin 280-289 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 25556489-5 2014 Bioinformatics analysis and luciferase assays of Nrf2-3"-untranslated region-based reporter constructor indicated that Nrf2 was the direct target gene of miR- 340, miR-340 mimics suppressing Nrf2-dependent antioxidant pathway and enhancing the sensitivity of HepG2/ CDDP cells to cisplatin. Cisplatin 280-289 NFE2 like bZIP transcription factor 2 Homo sapiens 119-123 25556489-6 2014 Interestingly, transfection with miR-340 mimics combined with miR-340 inhibitors reactivated the Nrf2 related pathway and restored the resistance of HepG2/CDDP cells to CDDP. Cisplatin 155-159 NFE2 like bZIP transcription factor 2 Homo sapiens 97-101 25556489-7 2014 Collectively, the results first suggested that lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway. Cisplatin 109-113 NFE2 like bZIP transcription factor 2 Homo sapiens 198-202 23783243-6 2013 The focus of this review is to highlight recent work that has demonstrated an ability of Nrf2 to determine the sensitivity of the kidney to acute injury invoked by environmental insults such as heavy metals and ischemia, as well as xenobiotics such as cyclosporin A and cisplatin. Cisplatin 270-279 NFE2 like bZIP transcription factor 2 Homo sapiens 89-93 24046186-0 2013 4-methoxychalcone enhances cisplatin-induced oxidative stress and cytotoxicity by inhibiting the Nrf2/ARE-mediated defense mechanism in A549 lung cancer cells. Cisplatin 27-36 NFE2 like bZIP transcription factor 2 Homo sapiens 97-101 24046186-3 2013 In the present study, we aimed to find small molecule compounds that enhance the sensitivity of tumor cells to cisplatin induced cytotoxicity by suppressing Nrf2-mediated defense mechanism. Cisplatin 111-120 NFE2 like bZIP transcription factor 2 Homo sapiens 157-161 24046186-4 2013 A549 lung cancer cells were shown to be more resistant to the anti-cancer drug cisplatin than HEK293 cells, with higher Nrf2 signaling activity; constitutively high amounts of Nrf2-downstream target proteins were observed in A549 cells. Cisplatin 79-88 NFE2 like bZIP transcription factor 2 Homo sapiens 120-124 24046186-4 2013 A549 lung cancer cells were shown to be more resistant to the anti-cancer drug cisplatin than HEK293 cells, with higher Nrf2 signaling activity; constitutively high amounts of Nrf2-downstream target proteins were observed in A549 cells. Cisplatin 79-88 NFE2 like bZIP transcription factor 2 Homo sapiens 176-180 24046186-8 2013 This inhibition of Nrf2 signaling results in the accelerated generation of reactive oxygen species and exacerbation of cytotoxicity in cisplatin-treated A549 cells. Cisplatin 135-144 NFE2 like bZIP transcription factor 2 Homo sapiens 19-23 24046186-9 2013 Taken together, these results suggest that the small molecule compound 4-MC could be used to enhance the sensitivity of tumor cells to the therapeutic effect of cisplatin through the regulation of Nrf2/ARE signaling. Cisplatin 161-170 NFE2 like bZIP transcription factor 2 Homo sapiens 197-201 21489257-7 2011 RNAi depletion of Nrf2 caused a decrease in the proliferation of Suit-2, MiaPaca-2 and FAMPAC cells and enhanced sensitivity to gemcitabine (Suit-2), 5-flurouracil (FAMPAC), cisplatin (Suit-2 and FAMPAC) and gamma radiation (Suit-2). Cisplatin 174-183 NFE2 like bZIP transcription factor 2 Homo sapiens 18-22 23387073-0 2012 [Schisandrin B protects against nephrotoxicity induced by cisplatin in HK-2 cells via Nrf2-ARE activation]. Cisplatin 58-67 NFE2 like bZIP transcription factor 2 Homo sapiens 86-90 23387073-12 2012 These results suggested Sch B could protect against the oxidative damage of HK-2 cells induced by cisplatin via the activation of Nrf2/ARE signal pathway. Cisplatin 98-107 NFE2 like bZIP transcription factor 2 Homo sapiens 130-134 22465804-0 2012 Eriodictyol-7-O-glucoside, a novel Nrf2 activator, confers protection against cisplatin-induced toxicity. Cisplatin 78-87 NFE2 like bZIP transcription factor 2 Homo sapiens 35-39 22465804-4 2012 Recent studies have suggested that activation of Nrf2 pathway would confer protection against cisplatin-induced toxicity. Cisplatin 94-103 NFE2 like bZIP transcription factor 2 Homo sapiens 49-53 22465804-7 2012 These findings demonstrated the feasibility of using natural compounds targeting Nrf2 as a therapeutic approach to subvert the side effects of cisplatin in normal cells. Cisplatin 143-152 NFE2 like bZIP transcription factor 2 Homo sapiens 81-85 21205897-5 2011 Here, we report the identification of brusatol as a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells and A549 xenografts to cisplatin and other chemotherapeutic drugs. Cisplatin 161-170 NFE2 like bZIP transcription factor 2 Homo sapiens 76-80 21128686-7 2011 Confocal microscopy experiments, enzyme assay, and Western blotting of proteins regulated by Nrf2 provided evidences that this pathway, playing a protective role in normal cells, may represent a potential novel target to control cisplatin resistance in neuroblastoma. Cisplatin 229-238 NFE2 like bZIP transcription factor 2 Homo sapiens 93-97 19345732-11 2009 Finally, we found that silencing Nrf2 also increased the toxicity of cisplatin in H358 cells. Cisplatin 69-78 NFE2 like bZIP transcription factor 2 Homo sapiens 33-37 21857081-10 2011 These results demonstrate that the expression of HO-1 induced by phloretin is mediated by both the JNK pathway and Nrf2; the expression inhibits cisplatin-induced apoptosis in HEI-OC1 cells. Cisplatin 145-154 NFE2 like bZIP transcription factor 2 Homo sapiens 115-119 20723361-0 2009 [Expression and significance of nrf2 and its target genes in pulmonary adenocarcinoma a549 cells resistant to Cisplatin.]. Cisplatin 110-119 NFE2 like bZIP transcription factor 2 Homo sapiens 32-36 20723361-2 2009 It has been proved that Nrf2 is relevant to cisplatin-resistance in ovarian cancer cells. Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 24-28 20723361-3 2009 Up to now, little is know whether Nrf2 and it"s signal patheways play an important role in cisplatin-resistance in pulmonary adenocarcinoma cells or not. Cisplatin 91-100 NFE2 like bZIP transcription factor 2 Homo sapiens 34-38 20723361-4 2009 The aim of this study is to explore the expression levels of transcription factor Nrf2 and its target genes in A549 cells which are resistance to cisplatin and reveal the mechanism behind it. Cisplatin 146-155 NFE2 like bZIP transcription factor 2 Homo sapiens 82-86 18584244-6 2008 Furthermore, WT-Nrf2 overexpression effectively blocked MAPK activation after cisplatin exposure. Cisplatin 78-87 NFE2 like bZIP transcription factor 2 Homo sapiens 16-20 19286452-0 2009 Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Cisplatin 19-28 NFE2 like bZIP transcription factor 2 Homo sapiens 60-64 19286452-12 2009 These results suggest that ebselen activates the Nrf2-ARE signaling pathway, which ultimately prevents free radical stresses from cisplatin and further contributes to protect auditory sensory hair cells from free radicals produced by cisplatin. Cisplatin 130-139 NFE2 like bZIP transcription factor 2 Homo sapiens 49-53 19286452-12 2009 These results suggest that ebselen activates the Nrf2-ARE signaling pathway, which ultimately prevents free radical stresses from cisplatin and further contributes to protect auditory sensory hair cells from free radicals produced by cisplatin. Cisplatin 234-243 NFE2 like bZIP transcription factor 2 Homo sapiens 49-53 19417020-5 2009 The resistance to cisplatin was significantly inhibited in A549 but not in NCI-H292 or LC-AI cells by knockdown of Nrf2 with its specific small interfering RNA (Nrf2-siRNA). Cisplatin 18-27 NFE2 like bZIP transcription factor 2 Homo sapiens 161-165 19417020-8 2009 The degree of DNA crosslink and apoptosis after treatment with cisplatin was significantly elevated in A549 cells by Nrf2-siRNA. Cisplatin 63-72 NFE2 like bZIP transcription factor 2 Homo sapiens 117-121 18584244-0 2008 Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1. Cisplatin 14-23 NFE2 like bZIP transcription factor 2 Homo sapiens 114-118 18584244-2 2008 We report here that flunarizine markedly attenuates cisplatin-induced pro-inflammatory cytokine secretion and their messenger RNA transcription as well as cisplatin cytotoxicity through the activation of Nrf2/HO-1 and downregulation of NF-kappaB. Cisplatin 52-61 NFE2 like bZIP transcription factor 2 Homo sapiens 204-208 18584244-3 2008 In HEI-OC1 cells, overexpression of Nrf2/HO-1 by gene transfer or pharmacological approaches attenuated cisplatin-induced cytotoxicity and pro-inflammatory cytokine production. Cisplatin 104-113 NFE2 like bZIP transcription factor 2 Homo sapiens 36-40 18584244-8 2008 These results indicate that flunarizine induces a protective effect against cisplatin ototoxicity through the downregulation of NF-kappaB by Nrf2/HO-1 activation and the resulting inhibition of pro-inflammatory cytokine production in vitro and in vivo. Cisplatin 76-85 NFE2 like bZIP transcription factor 2 Homo sapiens 141-145 17418561-8 2007 These results demonstrate that the expression of HO-1 by piperine is mediated by both JNK pathway and Nrf2, and the expression inhibits cisplatin-induced apoptosis in HEI-OC1 cells. Cisplatin 136-145 NFE2 like bZIP transcription factor 2 Homo sapiens 102-106 18413364-7 2008 In this study, we demonstrate the dark side of Nrf2: stable overexpression of Nrf2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents including cisplatin, doxorubicin and etoposide. Cisplatin 168-177 NFE2 like bZIP transcription factor 2 Homo sapiens 47-51 18413364-7 2008 In this study, we demonstrate the dark side of Nrf2: stable overexpression of Nrf2 resulted in enhanced resistance of cancer cells to chemotherapeutic agents including cisplatin, doxorubicin and etoposide. Cisplatin 168-177 NFE2 like bZIP transcription factor 2 Homo sapiens 78-82 18006113-0 2008 Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Cisplatin 107-116 NFE2 like bZIP transcription factor 2 Homo sapiens 15-19 18006113-8 2008 In addition, pharmacologic inhibitors of MAPK suppressed the induction of HO-1 and Nrf2 expression by cisplatin. Cisplatin 102-111 NFE2 like bZIP transcription factor 2 Homo sapiens 83-87 18006113-9 2008 These findings suggest that HO-1 may modulate the chemosensitivity of lung cancer A549 cells to cisplatin through the MAPK-Nrf2 pathway. Cisplatin 96-105 NFE2 like bZIP transcription factor 2 Homo sapiens 123-127 16485034-6 2006 These results suggest that Nrf2-driven transcriptional activation of ARE through PI3K-Akt signaling augments the generation of HO-1, which may be a critically important determinant in cellular response toward cisplatin and the cytoprotective effect of flunarizine against cisplatin. Cisplatin 209-218 NFE2 like bZIP transcription factor 2 Homo sapiens 27-31 16485034-0 2006 Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cisplatin 118-127 NFE2 like bZIP transcription factor 2 Homo sapiens 20-24 16485034-6 2006 These results suggest that Nrf2-driven transcriptional activation of ARE through PI3K-Akt signaling augments the generation of HO-1, which may be a critically important determinant in cellular response toward cisplatin and the cytoprotective effect of flunarizine against cisplatin. Cisplatin 272-281 NFE2 like bZIP transcription factor 2 Homo sapiens 27-31 16485034-3 2006 Overexpression of Nrf2 protected cells from cisplatin along with transcriptional activation of ARE to generate heme oxygenase-1 (HO-1). Cisplatin 44-53 NFE2 like bZIP transcription factor 2 Homo sapiens 18-22